<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327924</url>
  </required_header>
  <id_info>
    <org_study_id>GH-3870</org_study_id>
    <secondary_id>U1111-1119-8619</secondary_id>
    <nct_id>NCT01327924</nct_id>
  </id_info>
  <brief_title>Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone</brief_title>
  <official_title>Ease of Use and Tolerability of Norditropin NordiFlex® in Growth Hormone naïve Children: Impact on Daily Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Europe. The purpose of this study is to assess the impact on daily
      life for children new to using a growth hormone injection device.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Usability of growth hormone injection device assessed by a quantitative scale</measure>
    <time_frame>after 3 months of growth hormone treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>from 0 - 3 months of growth hormone treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of technical complaints</measure>
    <time_frame>from 0 to 3 months of growth hormone treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">77</enrollment>
  <condition>Growth Hormone Disorder</condition>
  <condition>Growth Hormone Deficiency in Children</condition>
  <condition>Genetic Disorder</condition>
  <condition>Turner Syndrome</condition>
  <condition>Foetal Growth Problem</condition>
  <condition>Small for Gestational Age</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Chronic Renal Insufficiency</condition>
  <condition>Delivery Systems</condition>
  <arm_group>
    <arm_group_label>Norditropin NordiFlex® users</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norditropin NordiFlex®</intervention_name>
    <description>Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.</description>
    <arm_group_label>Norditropin NordiFlex® users</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Growth hormone treatment naïve children for whom a prescription of Norditropin NordiFlex®
        is initiated according to the SPC (Summary of Product Characteristics)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Growth hormone (GH) treatment naïve subjects for whom it has been decided to initiate
             GH treatment prior to enrollment into the study

          -  Subjects who receive Norditropin NordiFlex® according to the SPC

        Exclusion Criteria:

          -  Known or suspected allergy to study product(s) or related products

          -  Child and/or parent unable to give consent or fill out the questionnaires

          -  The receipt of any investigational medicinal product within 3 months prior to this
             study

          -  Suffer from a life-threatening disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Paris La défense cedex</city>
        <zip>92932</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2011</study_first_submitted>
  <study_first_submitted_qc>March 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2011</study_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
    <mesh_term>Turner Syndrome</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

